

In the claims:

1. (Currently amended) A method for the inhalation of a dry powder drug, the method comprising:
providing a dry powder drug composition comprising particles comprising a lipid matrix and a particle size of 1-30 microns, mass median aerodynamic diameter of less than 5 microns, and bulk density of less than 0.5 g/cm³;
loading the composition into a passive dry powder inhaler having a resistance of from 0.01 to 0.30 (cmH₂O)^{1/2}/Lmin⁻¹; and
inhaling the drug composition from the inhaler,
wherein the emitted dose is at least 60% for flow rates from 10 to 60 liters per minute resulting in an emitted dose substantially independent of device resistance and lung deposition substantially independent of inhalation flow rate.
2. (Cancelled)
3. (Currently amended) A method according to claim 2 wherein the comprising an emitted dose is of at least 80% for flow rates from 10 to 60 liters per minute.
4. (Currently amended) A method according to claim 1 wherein the fine particle fraction is comprising a FPF_{4.5μ} of at least 60%.
5. (Original) A method according to claim 1 wherein the lipid comprises a phospholipid selected from the group consisting of dipalmitoylphosphatidylcholine, distearylphosphatidylcholine, diarachidoylphosphatidylcholine, dibehenoylphosphatidylcholine, diphosphatidyl glycerol, short-chain phosphatidylcholines, long-chain saturated phosphatidylethanolamines, long-chain saturated phosphatidylserines, long-chain saturated phosphatidylglycerols, and long-chain saturated phosphatidylinositols.
- 6-10. (Cancelled)
11. (Currently amended) A method according to ~~of~~ claim 1 wherein the lung deposition is greater than 25%.

12. (Original) A method according to claim 1 wherein the lung deposition is greater than 30%.
13. (Original) A method according to claim 1 wherein the lung deposition is greater than 50%.
14. (Original) A method according to claim 1 wherein the drug is selected from the group consisting of budesonide, tobramycin sulfate, leuprolide acetate, Amphotericin B, and PTH.
15. (Currently amended) A method according to ~~of~~-claim 1 wherein the powder comprises hollow porous microparticles.
- 16-20. (Cancelled)